SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and
manufacturer of the only touchscreen insulin pumps available in the
United States, today announced the issuance of U.S. Patent No.
9,737,656 titled "Integration of Infusion Pump with Remote
Electronic Device". The patent generally relates to using a software
application operating on a remote consumer electronic device to
initiate, program and deliver a medicament bolus to a patient using a
medical infusion pump where the pump provides an indication of the
bolus, such as by an audible or vibration alert.
"The operation of an insulin pump using a consumer electronic device,
such as a smart phone, is a top area of interest in our next generation
pump development efforts," said Kim Blickenstaff, President and Chief
Executive Officer of Tandem Diabetes Care. "As the only Company with
experience in the use of touchscreen insulin pump control, we are
uniquely positioned to identify new and novel ways to safely utilize the
computing power of our everyday consumer devices to operate a
life-sustaining infusion pump. This patent reflects our foresight to
integrate consumer and medical device technologies to further our
mission to simplify the lives of people with diabetes and covers key
features we believe will be beneficial for commercial adoption in the
future."
U.S. Patent No. 9,737,656 expires in 2035. The Company has a
related U.S. continuation application on file, as well as a pending
application in Europe.
This newly issued patent raises Tandem Diabetes Care's patent portfolio
to 56 issued U.S. patents and 50 pending U.S. patent applications. In
addition, the Company has, and is seeking, patent protection for
proprietary technologies in other countries throughout the world.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company with an innovative, user-centric and
integrated approach to the design, development and commercialization of
products for people with diabetes who use insulin. The Company
manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and
smallest durable insulin pump currently on the market, the t:flex®
Insulin Pump, the first pump designed for people with greater insulin
requirements, and the t:slim G4™ Insulin Pump, the first continuous
glucose monitoring-enabled pump with touch-screen simplicity. Tandem is
based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2,
#tslimG4, #tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care
on Facebook at www.facebook.com/TandemDiabetes.
Follow
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
Tandem Diabetes Care, t:connect and t:flex are registered trademarks,
and t:slim X2 and t:slim G4 are trademarks of Tandem Diabetes Care, Inc.
All other trademarks are the property of their respective owners.
Forward Looking Statement
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
relate to, among other things the scope and enforceability of the
company's intellectual property, including the expected expiration of
the 9,737,656 patent, and whether the technology referenced in this
patent will beneficial for commercial adoption in the future. Many
factors could cause the company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by such
forward-looking statements, including without limitation, those listed
under the heading "Risk Factors" in the company's most recent Annual
Report on Form 10-K, Quarterly Report on Form 10-Q and other documents
that Tandem files with the Securities and Exchange Commission. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release. Tandem
undertakes no obligation to update or review any forward-looking
statement in this press release because of new information, future
events or other factors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170824006117/en/
Tandem Diabetes Care, Inc.
Media Contact:
Steve
Sabicer, 714-907-6264
ssabicer@thesabicergroup.com
or
Investor
Contact:
Susan Morrison, 858-366-6900 x7005
smorrison@tandemdiabetes.com
Source: Tandem Diabetes Care, Inc.
News Provided by Acquire Media
